MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2026-04-21

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Conditions

Interventions

DRUG

AVTX-009 Regimen 1

AVTX-009 will be administered as a subcutaneous injection every 4 weeks.

DRUG

AVTX-009 Regimen 2

AVTX-009 will be administered as a subcutaneous injection every 2 weeks.

DRUG

Placebo

Matching placebo will be administered as a subcutaneous injection every 2 weeks.

Sponsors & Collaborators

  • Avalo Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-16
Primary Completion
2026-02-23
Completion
2026-03-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • Greece
  • Italy
  • Poland
  • Slovakia
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06603077 on ClinicalTrials.gov